Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

European Treatment Outcome Study Score

Known as: EUTOS, European Treatment Outcome Study (EUTOS) Score 
A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high or low risk on the basis of the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2015
Review
2015
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology… Expand
  • table 2
  • table 3
  • figure 1
  • table 5
  • table 6
Is this relevant?
2014
2014
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients
The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2014
2014
The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid…
The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2013
2013
Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
This study set out to examine in a large real-life cohort of patients with chronic myeloid leukemia (CML) the impact of imatinib… Expand
Is this relevant?
2012
2012
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
To validate the recently reported European Treatment and Outcomes Study (EUTOS) score, we applied it to 465 patients with early… Expand
  • table 1
  • figure 1
  • figure 1
  • figure 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2011
2011
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.
TO THEEDITOR: In 1984, Sokal et al 1 developed a scoring system to predict the outcome of patients with chronic myeloid leukemia… Expand
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE